Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kodiak Sciences Inc.

Latest From Kodiak Sciences Inc.

Kodiak Turns Back On Tarcocimab After Two Pivotal Trial Flops In DME

The US firm’s lead antibody biopolymer conjugate asset failed to match Regeneron/Bayer’s Eylea in two Phase III diabetic macular edema studies, prompting discontinuation of the program and a reassessment of an earlier program based on the same platform technology.

Clinical Trials Ophthalmic

Kodiak’s KSI-301 Has Narrower Path Forward After Phase II/III Failure In Wet AMD

Monthly dosing remains a possibility in wet age-related macular degeneration, though diabetic macular edema and retinal vein occlusion look more promising.

Ophthalmic Business Strategies

Five Pivotal Trial Read-Outs To Look Out For In Early 2022

Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.

Clinical Trials Companies

Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD

Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.

Clinical Trials Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Oligasis LLC